Literature DB >> 9564467

Activity of amoxicillin/clavulanate in patients with tuberculosis.

H F Chambers1, T Kocagöz, T Sipit, J Turner, P C Hopewell.   

Abstract

Some beta-lactam antibiotics are active in vitro against Mycobacterium tuberculosis. There are anecdotal reports of successful treatment of tuberculosis caused by multiple-drug-resistant strains of M. tuberculosis with regimens that included amoxicillin/clavulanate. Reduction of M. tuberculosis in the sputum of patients with pulmonary tuberculosis during administration of amoxicillin/clavulanate was measured by a quantitative culture method to determine the activity in vivo. Patients were randomized to receive isoniazid, ofloxacin, or amoxicillin/clavulanate for 7 days. Isoniazid was the most effective agent, reducing M. tuberculosis after 2 days at a mean rate (+/- standard deviation) of 0.60 +/- 0.30 log10 cfu/mL per day, compared with 0.32 +/- 0.05 and 0.34 +/- 0.03 for ofloxacin and amoxicillin/clavulanate, respectively. The early bactericidal activity of amoxicillin/clavulanate was comparable to that reported for antituberculous agents other than isoniazid. Further studies of beta-lactam antibiotics with in vitro activity against M. tuberculosis are warranted to define their role in treatment of tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564467     DOI: 10.1086/513945

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  55 in total

Review 1.  Drug-resistant tuberculosis: what do we do now?

Authors:  A Telenti; M Iseman
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 2.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

Review 3.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

Review 4.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

5.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

6.  Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Authors:  Shiqi Xiao; Haidan Guo; Warren S Weiner; Clinton Maddox; Chunhong Mao; Hendra Gunosewoyo; Shaaretha Pelly; E Lucile White; Lynn Rasmussen; Frank J Schoenen; Jeffrey Aubé; William R Bishai; Shichun Lun
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

7.  Reconsidering some approved antimicrobial agents for tuberculosis.

Authors:  Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

8.  Transmitted Extended-Spectrum Extensively Drug-Resistant Tuberculosis in Beijing, China, with Discordant Whole-Genome Sequencing Analysis Results.

Authors:  Hao Li; Masood ur Rehman Kayani; Yunting Gu; Xiaobo Wang; Ting Zhu; Hongfei Duan; Yifeng Ma; Hairong Huang; Babak Javid
Journal:  J Clin Microbiol       Date:  2015-06-10       Impact factor: 5.948

9.  The role of the β5-α11 loop in the active-site dynamics of acylated penicillin-binding protein A from Mycobacterium tuberculosis.

Authors:  Alena Fedarovich; Robert A Nicholas; Christopher Davies
Journal:  J Mol Biol       Date:  2012-02-23       Impact factor: 5.469

10.  Clinical effects of gemifloxacin on the delay of tuberculosis treatment.

Authors:  Seo Yun Kim; Jae-Joon Yim; Jong Sun Park; Sung Soo Park; Eun Young Heo; Chang-Hoon Lee; Hee Soon Chung; Deog Kyeom Kim
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.